Spinal Modulation closes enrollment in Axium chronic pain study

Spinal Modulation closes enrollment in a U.S. pivotal study of its Axium neurotransmitter system for the treatment of chronic pain.

Spinal Modulation said it completed enrollment in a U.S. pivotal study of its Axium neurotransmitter system for the treatment of chronic pain.

Spinal Modulation, St. Jude Medical

News Well, Clinical Trials, Neuromodulation/Neurostimulation, Pain Management

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1GevZih